Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis

A. Chewcharat¹, C. Thongprayoon², B. Boonpheng³, A. Torres-Ortiz⁴, M. A Mao², N. J Khoury⁵, W. Cheungpasitporn⁴

¹Harvard T.H. Chan, Boston, MA, ²Mayo Clinic, Rochester, MN, ³East Tennessee State University, Johnson City, TN, ⁴University of Mississippi Medical Center, Jackson, MS, ⁵Henry Ford Hospital, Detroit, MI

Meeting: 2019 American Transplant Congress

Abstract number: D340

Keywords: Kidney transplantation, Malignancy, Mortality, Post-transplant malignancy

Session Information

Session Name: Poster Session D: PTLD/Malignancies: All Topics

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: The incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation (KTx) remain unclear. This study’s aims were 1) to investigate the pooled incidence/incidence trends and 2) to assess the mortality/mortality trends in KTx patients with RCC

*Methods: A literature search was conducted using MEDLINE, EMBASE and Cochrane databases from inception through October 2018. Studies that reported incidence or mortality of RCC among kidney transplant recipients were included. Pooled incidence and 95%CI were calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO; no. CRD42018108994.

*Results: Eighteen observational studies with a total of 310,111 KTx patients were enrolled. Overall, the pooled estimated incidence of RCC after KTx was 0.6% (95%CI: 0.4%-0.7%). While the pooled estimated incidence of RCC in the native kidney was 0.7% (95%CI: 0.5%-0.8%), the pooled estimated incidence of RCC in the allograft kidney was 0.3% (95%CI: 0.1%-0.8%). The pooled estimated mortality rate in KTx recipients with RCC was 8.4% (95%CI: 4.0%-16.9%) at a mean follow-up time of 36 months after RCC diagnosis. While meta-regression analysis showed a significant negative correlation between year of study and incidence of RCC post KTx (slopes = -0.06, P = 0.02), there was no significant correlation between the year of study and mortality of patients with RCC (P = 0.94). Egger’s regression asymmetry test was performed and showed no publication bias in all analyses. The data on incidence and mortality of recurrent RCC among KTx recipients with previous history of RCC prior to KTx were limited. A prior study demonstrated an incidence of recurrent RCC after KTx of 9.1% with associated 5-year survival of 41.7%.

*Conclusions: The overall estimated incidence of RCC after KTx is 0.6%. Although there have been potential improvements in incidence of RCC post KTx, mortality in KTx patients with RCC has not decreased over time.

To cite this abstract in AMA style:

Chewcharat A, Thongprayoon C, Boonpheng B, Torres-Ortiz A, Mao MA, Khoury NJ, Cheungpasitporn W. Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-and-mortality-of-renal-cell-carcinoma-after-kidney-transplantation-a-meta-analysis/. Accessed May 12, 2025.

« Back to 2019 American Transplant Congress